Literature DB >> 8109944

Antimicrobial susceptibilities of Gardnerella vaginalis.

A B Kharsany1, A A Hoosen, J Van den Ende.   

Abstract

The in vitro susceptibilities of 93 clinical isolates of Gardnerella vaginalis to 25 antimicrobial agents were determined by the agar dilution method. All isolates were susceptible to penicillin, ampicillin, erythromycin, clindamycin, chloramphenicol, and trimethoprim. Activity was poor for vancomycin, LY146032, the cephalosporins, ciprofloxacin, and imipenem. Some resistance was observed with tetracycline and minocycline. The MICs of metronidazole paralleled those of tinidazole, with the hydroxymetabolite of metronidazole being the most active. One strain was resistant to all three agents. Marked resistance to aztreonam, amikacin, and sulfamethoxazole was observed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8109944      PMCID： PMC192794          DOI： 10.1128/AAC.37.12.2733

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis.

Authors:  H L GARDNER; C D DUKES
Journal:  Am J Obstet Gynecol       Date:  1955-05       Impact factor: 8.661

2.  Heretofore undescribed organism isolated from the genitourinary system.

Authors:  S LEOPOLD
Journal:  U S Armed Forces Med J       Date:  1953-02

3.  Neonatal meningitis due to Gardnerella vaginalis.

Authors:  L Berardi-Grassias; O Roy; J C Berardi; J Furioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

4.  Delivery volumes of the 1- and 3-mm pins of a Cathra replicator.

Authors:  D Rousseau; P S Harbec
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

5.  Haemophilus vaginalis 594, a gram-negative organism?

Authors:  B S Criswell; J H Marston; W A Stenback; S H Black; H L Gardner
Journal:  Can J Microbiol       Date:  1971-07       Impact factor: 2.419

6.  Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis.

Authors:  S Hillier; M A Krohn; D H Watts; P Wolner-Hanssen; D Eschenbach
Journal:  Obstet Gynecol       Date:  1990-09       Impact factor: 7.661

7.  Gardnerella vaginalis bacteremia: a review of thirty cases.

Authors:  L G Reimer; L B Reller
Journal:  Obstet Gynecol       Date:  1984-08       Impact factor: 7.661

8.  In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis.

Authors:  B M Jones; I Geary; A B Alawattegama; G R Kinghorn; B I Duerden
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

9.  Ineffectiveness of erythromycin for treatment of Haemophilus vaginalis-associated vaginitis: possible relationship to acidity of vaginal secretions.

Authors:  M A Durfee; P S Forsyth; J A Hale; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  Relative susceptibilities of Gardnerella vaginalis (Haemophilus vaginalis), Neisseria gonorrhoeae, and Bacteroides fragilis to Metronidazole and its two major metabolites.

Authors:  E D Ralph; Y E Amatnieks
Journal:  Sex Transm Dis       Date:  1980 Oct-Dec       Impact factor: 2.830
View more
  10 in total

1.  Gardnerella vaginalis population dynamics in bacterial vaginosis.

Authors:  D W Hilbert; J A Schuyler; M E Adelson; E Mordechai; J D Sobel; S E Gygax
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-14       Impact factor: 3.267

2.  Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.

Authors:  M N Austin; R H Beigi; L A Meyn; S L Hillier
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Growth inhibition of metronidazole-susceptible and metronidazole-resistant strains of Gardnerella vaginalis by Lactobacilli in vitro.

Authors:  N W McLean; J A McGroarty
Journal:  Appl Environ Microbiol       Date:  1996-03       Impact factor: 4.792

4.  In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?

Authors:  Giuseppe Togni; Valeria Battini; Anna Bulgheroni; Federico Mailland; Maurizio Caserini; Werner Mendling
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

5.  Use of a continuous-culture biofilm system to study the antimicrobial susceptibilities of Gardnerella vaginalis and Lactobacillus acidophilus.

Authors:  F Muli; J K Struthers
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Drawing the line between commensal and pathogenic Gardnerella vaginalis through genome analysis and virulence studies.

Authors:  Michael D Harwich; Joao M Alves; Gregory A Buck; Jerome F Strauss; Jennifer L Patterson; Aminat T Oki; Philippe H Girerd; Kimberly K Jefferson
Journal:  BMC Genomics       Date:  2010-06-11       Impact factor: 3.969

Review 7.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

8.  Antibiotic susceptibility of Atopobium vaginae.

Authors:  Ellen De Backer; Rita Verhelst; Hans Verstraelen; Geert Claeys; Gerda Verschraegen; Marleen Temmerman; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2006-03-16       Impact factor: 3.090

9.  Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate.

Authors:  Jessica A Schuyler; Sean G Chadwick; Eli Mordechai; Martin E Adelson; Scott E Gygax; David W Hilbert
Journal:  Genome Announc       Date:  2015-09-03

10.  Draft Genome Sequence of a Metronidazole-Resistant Derivative of Gardnerella vaginalis Strain ATCC 14019.

Authors:  Jessica A Schuyler; Eli Mordechai; Martin E Adelson; Scott E Gygax; David W Hilbert
Journal:  Genome Announc       Date:  2015-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.